KEEPsAKE 2: Risankizumab improves signs, symptoms in refractory PsA

Sumary of KEEPsAKE 2: Risankizumab improves signs, symptoms in refractory PsA:

  • Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis, Including Patients With Inadequate Response or Intolerance to Biologic Therapies:.
  • Risankizumab is linked to significantly greater improvements in psoriatic arthritis signs and symptoms than placebo in patients with an inadequate response, or intolerance, to other drugs, according to a speaker at the EULAR 2021 Congress..
  • “Risankizumab is a humanized immunoglobulin G1 monoclonal antibody that binds to the p19 subunit of IL-23 and selectively inhibits this cytokine..
  • “Risankizumab was well tolerated with a safety profile consistent with that established for risankizumab in the treatment of moderate-to-severe psoriasis.”.
  • Adobe Stock “This is the phase-3 risankizumab psoriatic arthritis program, which included two randomized, double-blind, placebo-controlled studies,”.
  • “KEEPsAKE 1 was risankizumab versus placebo in adults with active psoriatic arthritis who have a history of inadequate response or intolerance to at least one disease-modifying antirheumatic drug therapy..
  • KEEPsAKE 2 was risankizumab versus placebo in adults with active PsA who have a history of inadequate response or intolerance to one or two biologic therapies or to at least one DMARD therapy.”.
  • A total of 444 participants were randomized, with 224 assigned to receive 150 mg of subcutaneous risankizumab at weeks 0, 4 and 16….

Want to know more click here go to source.

From -
Close
Generic selectors
Exact matches only
Search in title
Search in content

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close